Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 9/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928446 | 0.93 | MAPT (0.67) | RAB9AMAPTTP53POLBKMT2A | |
| SCHEMBL2923933 | 0.91 | RAB9A (0.74) | RAB9AMAPTTP53POLBKMT2A | |
| SCHEMBL2926158 | 0.87 | KMT2A (0.70) | RAB9AMAPTTP53POLBKMT2A | |
| SCHEMBL2930576 | 0.85 | RAB9A (0.86) | RAB9AMAPTTP53POLBKMT2A | |
| SCHEMBL2929724 | 0.85 | KMT2A (0.79) | RAB9AMAPTTP53POLBKMT2A | |
| SCHEMBL2923495 | 0.84 | TP53 (0.77) | RAB9AMAPTTP53POLBKMT2A | |
| SCHEMBL2926230 | 0.83 | TP53 (0.70) | RAB9AMAPTTP53POLBKMT2A | |
| SCHEMBL2923701 | 0.82 | MAPT (0.82) | RAB9AMAPTTP53POLBKMT2A | |
| SCHEMBL2929851 | 0.82 | RAB9A (0.75) | RAB9AMAPTTP53POLBKMT2A | |
| SCHEMBL2929084 | 0.80 | RAB9A (0.81) | RAB9AMAPTTP53POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431602-B2 | Beta-amino acid derivatives for treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-30 | — | — | US | claimed |
| EP-2231640-B1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2012-06-06 | — | — | EP | claimed |
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-12-30 | — | — | US | claimed |
| CN-101925596-B | Beta-amino acid derivatives for treatment of diabetes | MERCK PATENT GMBH | 2014-05-28 | — | — | CN | disclosed |
| US-8431602-B2 | Beta-amino acid derivatives for treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431602-B2 | Beta-amino acid derivatives for treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-30 | — | — | US | disclosed |
| EP-2231640-B1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-12-30 | — | — | US | disclosed |
| CN-101925596-A | Beta-amino acid derivatives for treatment of diabetes | MERCK PATENT GMBH | 2010-12-22 | — | — | CN | disclosed |
| WO-2009092432-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | GPR119, GLS, GCKR | RAB9A 2655/4885MAPT 3056/4885TP53 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.